MTP XIX: CLL   

Session Chair: Paolo Ghia

• Should We Note Subset 2 Positive Patients as a Specific Group Within Mutated or Unmutated CLL | Thomas Chatzikonstantinou, MD | Centre for Research and Technology Hellas, Thessaloniki, Greece
• MRD As a Surrogate for PFS/OS/Clinical Implications | Othman Al-Sawaf, MD | University Hospital Cologne, Cologne, Germany
• What Prognostic Models Should We Use | Stefano Molica, MD | Hull-York Medical School (HYMS), Hull, United Kingdom